Blurred Lines: Sponsor Role In FSD Patient Meeting Questioned
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At FDA’s female sexual dysfunction meeting, industry faces criticism for sponsoring patients to attend and backing a marketing campaign that calls for equality in approvals of drugs for male and female dysfunction.
You may also be interested in...
A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.
Disease-Awareness Ads Thrive In Regulatory No-Man’s Land
FDA says its hands are tied when it comes to curbing practices such as the testosterone ads its advisory committees have found problematic, but are the agency’s powers really that limited?
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.